European Biotech Acquisition Corp. (NASDAQ:EBAC – Get Rating) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 5,500 shares, a growth of 66.7% from the November 30th total of 3,300 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average trading volume of 16,900 shares, the days-to-cover ratio is currently 0.3 days.
Hedge Funds Weigh In On European Biotech Acquisition
Institutional investors have recently modified their holdings of the business. BNP Paribas Arbitrage SNC acquired a new position in shares of European Biotech Acquisition in the 3rd quarter valued at $3,691,000. Cubist Systematic Strategies LLC increased its holdings in shares of European Biotech Acquisition by 136.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 60,555 shares of the company's stock valued at $593,000 after acquiring an additional 34,896 shares during the period. Marshall Wace LLP increased its holdings in shares of European Biotech Acquisition by 3.9% in the 3rd quarter. Marshall Wace LLP now owns 453,992 shares of the company's stock valued at $4,504,000 after acquiring an additional 16,901 shares during the period. First Trust Capital Management L.P. acquired a new position in shares of European Biotech Acquisition in the 3rd quarter valued at $2,265,000. Finally, Glazer Capital LLC increased its holdings in shares of European Biotech Acquisition by 40.6% in the 3rd quarter. Glazer Capital LLC now owns 995,474 shares of the company's stock valued at $9,855,000 after acquiring an additional 287,251 shares during the period.
Get
European Biotech Acquisition alerts:
European Biotech Acquisition Stock Performance
Shares of European Biotech Acquisition stock traded up $0.02 during trading on Friday, reaching $10.10. The company's stock had a trading volume of 9,713 shares, compared to its average volume of 28,636. The company has a 50-day moving average price of $10.01 and a two-hundred day moving average price of $9.92. European Biotech Acquisition has a fifty-two week low of $9.66 and a fifty-two week high of $10.50.
About European Biotech Acquisition
(Get Rating)
European Biotech Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus on business in the life sciences industry in Europe.
Featured Stories
- Get a free copy of the StockNews.com research report on European Biotech Acquisition (EBAC)
- MarketBeat: Week in Review 12/26 – 12/30
- The Dogs Of Tech: It's Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Should You Warm up to Generac Stock for the Winter?
- Is Kintara Therapeutics A Hidden Gem?
Receive News & Ratings for European Biotech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for European Biotech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
